We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company


  Gold Thermo Fisher Scientific provides analytical instruments, lab equipment, specialty diagnostics, reagents and integrat... read more Featured Products: More products

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Natural Killer Cell-Associated Markers Investigated in Gastric Cancer

By LabMedica International staff writers
Posted on 11 Jan 2022
Print article
Image: Advanced stage of stomach cancer with stomach tissue array, including pathology grade, malignant tumors (TNM) and clinical stage (Photo courtesy of SuperBioChips Laboratories)
Image: Advanced stage of stomach cancer with stomach tissue array, including pathology grade, malignant tumors (TNM) and clinical stage (Photo courtesy of SuperBioChips Laboratories)
Gastric cancer (GC) is one of the leading causes of cancer-related deaths worldwide. Although the survival rates of GC patients have increased with proper screening systems, standardized surgical protocols, and development of chemotherapy regimens, the general outcome of GC patients, especially those in advanced stages, remains poor.

The importance of the tumor immune microenvironment (TME) has been well-established in the last two decades. Various immune cell populations and stromal cells in the TME and tumor cells play an important role by interacting with each other, leading to tumor suppression or progression. Characterizing the interactions between immune cells and tumor cells is critical to understand the TME.

Clinical Scientists at the Seoul National University College of Medicine (Seoul, Republic of Korea) recruited for a study a total of 55 cases of consecutive stage II-III GC surgically resected between 2006 and 2008. The formalin-fixed, paraffin-embedded (FFPE) tissue samples were reviewed, and representative tissue areas were dissected for the construct a tissue microarray (TMA). The team performed multiplex immunohistochemistry (mIHC) on the tissue microarrays slides. A total of 11 antibodies including CD57, NKG2A, CD16, HLA-E, CD3, CD20, CD45, CD68, CK, SMA, and ki-67 were used. CD45 + CD3-CD57 + cells were considered as CD57 + NK cells.

For molecular classification of the GC samples, conventional immunohistochemistry (IHC) for E-cadherin and p53 was performed on 3-μm-thick TMA slides using an automated BenchMark XT immunostainer (Ventana Medical Systems, Tucson, AZ USA). All implementations and analysis of mIHC were performed on the SuperBioChips (SuperBioChips Laboratories, Seoul, Korea). Polymerase chain reaction (PCR) amplification of the extracted DNA from tumor and normal cells was performed and the PCR products were analyzed using a DNA autosequencer, the ABI 3731 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

The investigators reported that among CD45 + immune cells, the proportion of CD57 + NK cell was the lowest (3.8%), whereas that of CD57 + and CD57- T cells (65.5%) was the highest, followed by macrophages (25.4%), and B cells (5.3%). CD57 + NK cells constituted 20% of CD45 + CD57 + immune cells while the remaining 80% were CD57 + T cells. The expression of HLA-E in tumor cells correlated with that in tumoral T cells, B cells, and macrophages, but not CD57 + NK cells. The higher density of tumoral CD57 + NK cells and tumoral CD57 + NKG2A + NK cells was associated with inferior survival.

The authors concluded that although the number of CD57 + NK cells was lower than that of other immune cells, CD57 + NK cells and CD57 + NKG2A + NK cells were significantly associated with poor outcomes, suggesting that NK cell subsets play a critical role in GC progression. NK cells and their inhibitory receptor, NKG2A, may be potential targets in GC. The study was published on December 24, 2021 in the Journal of Translational Medicine.

Related Links:
Seoul National University College of Medicine
Ventana Medical Systems
SuperBioChips Laboratories
Applied Biosystems

Gold Supplier
SARS-CoV-2 Assay
Gold Supplier
Automated Nucleic Acid Extraction Workstation
Glucose & Lactate Measuremen Device
Silver Supplier
Glass Beaker
Globe Glass Beakers, Griffin Style

Print article


Molecular Diagnostics

view channel
Image: New chip could make treating metastatic cancer easier and faster (Photo courtesy of Georgia Institute of Technology)

Simple Blood Test Detection Method Could Revolutionize Cancer Treatment

Cancer spreads via circulating tumor cells (CTCs) that travel through the blood to other organs, and they are nearly impossible to track. When a tumor starts metastasizing, it sheds its cell into the blood.... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.